Effect of Ribavirin, in Combination With Interferon in Patients With Hepatitis C, on the Bleeding Risk Associated With Selective Serotonin Reuptake Inhibitors

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: We read with great interest the recent article by Martinet al.¹ reporting that the bleeding risk associated with use of selectiveserotonin reuptake inhibitors (SSRIs) during antiviraltherapy for chronic hepatitis C (CHC) is lower than that previouslyreported.² Several reports had revealed the increasing riskof bleeding, including retinal hemorrhages or gastrointestinalbleeding, by administrating SSRIs to patients receiving interferon-α therapy.^3-6Ribavirin was used in combination with interferon in thetreatment of patients with CHC in the study by Martin et al.¹‘ ‹